[Immunocorrecting therapy of chronic bacterial prostatitis].
A total of 55 patients aged 20-59 years with recurrent chronic bacterial prostatitis (RCBP) entered a trial of immunomodulator panavir. The study group consisted of 40 patients. They were given standard treatment and panavir. The control group (n = 15) matched by all the studied characteristics received standard treatment only. Blood count, bacteriological characteristics of prostatic secretion, immunological status, subjective parameters were studied. RCBP patients were diagnosed to have marked disorders of interferon status. The addition of panavir to standard treatment of RCBP patients significantly improved treatment results. Therefore, panavir is recommended as an adjuvant in combined RCBP treatment.
A I
AI
Novikov
V V
VV
Zaezzhalkin
V A
VA
Kucherov
S Iu
SIu
Frolov
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D006027:Glycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D026741:Physical Therapy Modalities; D011472:Prostatitis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; D006027:Glycosides; D007155:Immunologic Factors; C520796:Panavir (Solanum tuberosum)